

## STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1/ Line 2-3	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2/ Line 34-60	Abstract/ Paragraph 1-4
<b>Introduction</b>				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 3 /Line 68-Page 4/Line 110	Introduction/ Paragraph 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4/ Line 108-110	Introduction/ Paragraph 3
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	Page 4/ Line 114-Page 5/ Line 127	Methods/ Paragraph 1-2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4/ Line 114-Page 5/ Line 138	Methods/ Paragraph 1-3
Participants	6	(a) <b>Cohort study</b> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <b>Case-control study</b> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <b>Cross-sectional study</b> —Give the eligibility criteria, and the sources and methods of selection of participants	Page 4/ Line 114-Page 5/ Line 127	Methods/ Paragraph 1-2
		(b) <b>Cohort study</b> —For matched studies, give matching criteria and number of exposed and unexposed <b>Case-control study</b> —For matched studies, give matching criteria and the number of controls per case	N/A, the study is not a matched study.	N/A, the study is not a matched study.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5 /Line 139-151	Methods/ Paragraph 4-5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 5 /Line 139-151	Methods/ Paragraph 4-5

Bias	9	Describe any efforts to address potential sources of bias	Page 5 /Line 131-134 Page 5 /Line 143-145	Methods/ Paragraph 3-4
Study size	10	Explain how the study size was arrived at	Page 6 /Line 169-176	Results/ Paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 5 /Line 139-151	Methods/ Paragraph 4-5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 6 /Line 158-164	Methods/ Paragraph 7
		(b) Describe any methods used to examine subgroups and interactions	N/A, subgroup analysis was not conducted in the study.	N/A, subgroup analysis was not conducted in the study.
		(c) Explain how missing data were addressed	Page 6 /Line 164	Methods/ Paragraph 7
		(d) <b>Cohort study</b> —If applicable, explain how loss to follow-up was addressed <b>Case-control study</b> —If applicable, explain how matching of cases and controls was addressed <b>Cross-sectional study</b> —If applicable, describe analytical methods taking account of sampling strategy	Page 6 /Line 164	Methods/ Paragraph 7
		(e) Describe any sensitivity analyses	N/A, sensitivity analysis was not conducted in the study.	N/A, sensitivity analysis was not conducted in the study.
<b>Results</b>				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 6 /Line 169-176	Results/ Paragraph 1
		(b) Give reasons for non-participation at each stage	Page 5 /Line 124-127 Page 6 /Line 169-176	Methods/ Paragraph 2 Results/ Paragraph 1
		(c) Consider use of a flow diagram	Page 21 /Line 521	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 6/Line 181- Page 7/Line 120	Results/ Paragraph 2-3

		(b) Indicate number of participants with missing data for each variable of interest	Page 6 /Line 174	Results/ Paragraph 1
		(c) <b>Cohort study</b> —Summarise follow-up time (eg, average and total amount)	N/A, the study did not follow up patients.	N/A, the study did not follow up patients.
Outcome data	15*	<b>Cohort study</b> —Report numbers of outcome events or summary measures over time	Page 17/Line 509- Page 20/Line 520	Table 2-5
		<b>Case-control study</b> —Report numbers in each exposure category, or summary measures of exposure	N/A, not Case-control study	N/A, not Case-control study
		<b>Cross-sectional study</b> —Report numbers of outcome events or summary measures	N/A, not Cross-sectional study	N/A, not Cross-sectional study
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 7/Line 201- Page 8 /Line 238	Results/Paragraph 4-8
		(b) Report category boundaries when continuous variables were categorized	Page 5/Line 148-151	Methods/ Paragraph 5
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A, irrelevant	N/A, irrelevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A, No other analysis	N/A, No other analysis
<b>Discussion</b>				
Key results	18	Summarise key results with reference to study objectives	Page 12/ Line 379- 390	Conclusion/ Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 12/ Line 367- 375	Discussion/ Paragraph 8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 8/ Line 241- Page 12/Line 366	Discussion/ Paragraph 1- 7
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 12/ Line 368- 370	Conclusion/ Paragraph 2
<b>Other information</b>				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 13/ Line 394	Acknowledgments/ Paragraph 1

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

Article information: <https://dx.doi.org/10.21037/tp-23-79>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.

Updated on April 13, 2020